Phospholipase Cδ1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
• Activating KRAS mutations in CRC predict poor response to EGF receptor-targeted therapies.
• Phospholipase Cδ1 (PLCδ1) expression is potentially linked to KRAS mutation status in CRC, but its role is unknown.

Purpose of the Study:

• To investigate the role and regulatory mechanisms of PLCδ1 in colorectal cancer.
• To determine if PLCδ1 expression is altered in CRC tissues and cell lines.
• To elucidate the functional impact of PLCδ1 on CRC cell behavior and signaling pathways.

Main Methods:

• Immunohistochemistry to assess PLCδ1 expression in CRC specimens versus normal colon epithelium.
• Ectopic expression and knockdown of PLCδ1 in CRC cell lines with activating KRAS mutations.
• Analysis of E-cadherin and mesenchymal gene expression.
• Assessment of cell motility, invasiveness, and in vivo tumorigenicity.
• Investigation of the KRAS/MEK/ERK signaling pathway's effect on PLCδ1 and vice versa.

Main Results:

• PLCδ1 expression is significantly down-regulated in CRC tissues compared to normal colon tissue.
• Ectopic PLCδ1 expression increased E-cadherin and suppressed mesenchymal gene expression in CRC cells.
• Overexpression of PLCδ1 reduced CRC cell motility, invasiveness, and in vivo tumor growth.
• The KRAS/MEK pathway represses PLCδ1 expression.
• PLCδ1 suppressed ERK1/2 phosphorylation via E-cadherin induction, forming a negative feedback loop.

Conclusions:

• PLCδ1 exhibits tumor-suppressive functions in colorectal cancer.
• PLCδ1 exerts its effects by inducing E-cadherin and attenuating KRAS/MEK/ERK signaling.
• Down-regulation of PLCδ1 contributes to CRC progression and may be driven by the KRAS pathway.